Extended antiviral therapy may shield transplant patients from dangerous virus

NCT ID NCT06812598

Recruiting now Prevention Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving letermovir for a longer time (up to 28 weeks) can prevent cytomegalovirus (CMV) infection in Chinese adults who have a high risk of reactivation after a stem cell transplant. Participants must be at least 18, have had a stem cell transplant, and have certain risk factors like a mismatched donor or cord blood. The goal is to see if extended treatment reduces CMV-related complications without increasing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV CYTOMEGALOVIRUS INFECTIONS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hematology Department, The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

Contact Phone: •••-•••-•••• Email: •••••@•••••